Osteometer wins US market clearance for bone marker test
This article was originally published in Clinica
Executive Summary
The US FDA has cleared Osteometer Biotech's serum-based bone resorption test for monitoring antiresorptive therapy in patients with osteoporosis. The Serum CrossLaps One Step ELISA test, which detects collagen fragments released into circulation during bone resorption, can also be used as an early test for predicting the long-term skeletal response to antiresorptive treatments, such as Fosamax and hormone replacement therapy (HRT).